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Abstract
Insulin resistance is a common metabolic abnormality in women with PCOS and leads to an elevated risk of type 2 diabetes.
Studies have shown that thiazolidinediones (TZDs) improve metabolic disturbances in PCOS patients. We hypothesized that
the effect of TZDs in PCOS is, in part, mediated by changes in the transcriptional profile of muscle favoring insulin sensitivity.
Using Affymetrix microarrays, we examined the effect of pioglitazone (30 mg/day for 16 weeks) on gene expression in
skeletal muscle of 10 obese women with PCOS metabolically characterized by a euglycemic-hyperinsulinemic clamp.
Moreover, we explored gene expression changes between these PCOS patients before treatment and 13 healthy women.
Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting
serum insulin (all P,0.05). Global pathway analysis using Gene Map Annotator and Pathway Profiler (GenMAPP 2.1) and
Gene Set Enrichment Analysis (GSEA 2.0.1) revealed a significant upregulation of genes representing mitochondrial
oxidative phosphorylation (OXPHOS), ribosomal proteins, mRNA processing reactome, translation factors, and proteasome
degradation in PCOS after pioglitazone therapy. Quantitative real-time PCR suggested that upregulation of OXPHOS genes
was mediated by an increase in PGC-1a expression (P,0.05). Pretreatment expression of genes representing OXPHOS and
ribosomal proteins was down-regulated in PCOS patients compared to healthy women. These data indicate that
pioglitazone therapy restores insulin sensitivity, in part, by a coordinated upregulation of genes involved in mitochondrial
OXPHOS and ribosomal protein biosynthesis in muscle in PCOS. These transcriptional effects of pioglitazone may contribute
to prevent the onset of type 2 diabetes in these women.
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Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine and
metabolic disorder occurring in 5–10% of premenopausal women.
Symptoms of PCOS include menstrual irregularities, hyperandro-
genism, and infertility [1]. Several studies have shown that insulin
resistance plays an important role in the pathogenesis of PCOS [2]
and increases the risk for development of type 2 diabetes [1,2].
Thiazolidinediones (TZDs), including pioglitazone, are peroxisome
proliferator-activated receptor (PPAR)-c agonists that induce
adipogenesis and have insulin-sensitizing and antidiabetic properties
[3]. TZDs operate via receptor-dependent or independent mecha-
nisms thereby regulating the expression of genes involved in
mitochondrial biogenesis, insulin signal transduction, and glucose
and lipid metabolism [4,5]. PPARc is most abundantly expressed in
adipose tissue and to a lesser extent in muscle and liver tissue [6].
Recent studies have demonstrated that the beneficial metabolic
effects of treatment with pioglitazone in PCOS patients partly
occur through improvement of insulin sensitivity, including
increased insulin-stimulated total, oxidative and non-oxidative
glucose transport, and a decrease in insulin secretion [7,8], similar
to observations in patients with type 2 diabetes [9]. Skeletal muscle
accounts for the majority of insulin-stimulated glucose transport
suggesting an important role for TZDs in this tissue.
The mechanisms by which TZDs exert their insulin sensitizing
action in skeletal muscle of type 2 diabetic patients are not yet fully
understood, but may include increased downstream insulin
receptor signaling [10,11] and enhanced fatty acid uptake and
oxidation [12,13]. Moreover, animal studies have demonstrated
that prolonged treatment with TZDs is associated with increased
AMP-activated protein kinase (AMPK) activity [14], and increased
expression of NADH dehydrogenase subunit 1 of complex I and
PPAR-c coactivator-1a (PGC-1a) in skeletal muscle [15]. These
observations suggest that TZDs may increase insulin sensitivity, in
part, by improving mitochondrial oxidative metabolism (OX-
PHOS). We have recently demonstrated reduced expression of
genes involved in OXPHOS in skeletal muscle of insulin resistant
women with PCOS [16]. However, to our knowledge, no study
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2466has examined whether changes in muscle transcripts contribute to
the insulin sensitizing effect of TZDs in PCOS patients.
DNA microarrays are high throughput technologies aiming at
measuring transcript abundance for thousands of genes simulta-
neously [17]. To explore mRNA levels in diseases where differences
ingeneexpressionaretoomodestornumeroustoextractmeaningful
biological function from individual genes, the application of global
pathway analysis has been promising in detecting coordinated
changes in gene expression levels [16,18–20].
In the present study, we hypothesized that pioglitazone
treatment may modify the expression of pathways representing
OXPHOS genes as well as other pathways implicated in skeletal
muscle insulin resistance of PCOS patients. We used two different
approaches for global pathway analysis, and quantitative real-time
PCR (q-RT-PCR) was applied to evaluate microarray results.
Results
Clinical and metabolic characteristics
After treatment with pioglitazone, basal serum insulin levels were
reduced, whereas plasma adiponectin increased 2-fold (all P,0.01)
(Table 1). No significant changes in plasma triglycerides, basal
plasma glucose, serum free testosterone, or plasma FFA levels were
observed. Insulin-stimulated total glucose disposal was increased by
36%inPCOSpatientsinresponsetopioglitazone(P,0.01),and this
was partly accounted for by a 26% increase in glucose oxidation
(P,0.05) and a 50% increase in non-oxidative glucose metabolism
(P,0.01). There was no significant change in the ability of insulin to
suppress lipid oxidation in response to pioglitazone.
Pretreatment levels of plasma triglycerides (P,0.05), basal
serum insulin and free testosterone levels were elevated (P,0.01),
and plasma adiponectin tended to be decreased (P,0.07) in PCOS
patients compared with control subjects. There was no significant
difference with respect to basal plasma glucose and FFA. Insulin-
mediated total, non-oxidative and oxidative glucose metabolism
and suppression of lipid oxidation were impaired in PCOS
patients compared with control subjects (all P,0.01).
Oligonucleotide microarray analysis
Statistical analysis of the 54.675 probe sets represented on the
array revealed that 23.933 probe sets were differentially regulated
in PCOS patients in response to treatment with pioglitazone
(uncorrected P,0.05). 5.303 probe sets remained significantly
differentially expressed when corrected for multiple testing using
the Benjamini-Hochberg method (FDR,0.01) [21].
Pretreatment levels of 14.834 probe sets were differentially
expressed in PCOS patients compared with control subjects. After
correction for multiple testing (FDR,0.05), 2.754 probe sets
remained significantly differentially expressed [21]. To examine this
huge amount of regulated transcripts, we decided to apply global
pathway analysis to identify significantly regulated pathways.
Effects of pioglitazone evaluated by global pathway
analysis
The pathways that were regulated in skeletal muscle of PCOS
patients in response to pioglitazone treatment were examined by
Gene Map Annotator and Pathway Profiler (GenMAPP 2.1)
together with its accessory program, MAPPFinder 2.1, and by
gene set enrichment analysis (GSEA 2.0.1). Using MAPPFinder,
the top ranked upregulated pathways were ribosomal proteins, electron
transport chain, mRNA processing reactome, ubiquinone biosynthesis,
proteasome degradation, and translation factors (family wise error rate
(FWER) ,0.05) (Table 2). Applying GSEA, the electron transport
chain, VOXPHOS, insulin 2F up (genes 2 fold upregulated by insulin),
ribosomal proteins, mRNA splicing, mRNA processing, circadian exercise
(genes that regulate the 24-hour cycle), rapamycin_DN, glutamine_DN
(genes downregulated in response to rapamycin or glutamine
Table 1. Clinical and metabolic characteristics of PCOS patients and control subjects.
Control Subjects PCOS Pretreatment PCOS Posttreatment
n 13 10 10
Age (years) 34.762.0 30.362.1
Body mass index (kg/m
2) 34.061.8 33.260.9 33.061.1
Body fat (%) 4161.6 39.161.3 39.861.4
Plasma triglycerides (mmol/l) 0.8660.12 { 1.4360.22 1.1560.16
Serum free testosterone (nmol/l) 0.02560.003 {{ 0.05360.009 0.04860.007
Plasma glucose basal (mmol/l) 5.660.1 5.960.2 5.660.1
Serum insulin basal (pmol/l) 5166 {{ 125623 69612{{
Plasma FFA basal (mmol/l) 0.4960.04 0.4560.05 0.4160.05
Plasma adiponectin (mg/l) 9.460.8 7.160.9 16.162.2{{
Rd basal (mg?min
21?m
22)7 2 637 5 637 6 64
Rd clamp (mg?min
21?m
22) 290623 {{ 138618 188625{{
Glucose oxidation basal (mg?min
21?m
22)5 2 684 6 654 3 610
Glucose oxidation clamp (mg?min
21?m
22) 12465 {{ 80610 101612{
Lipid oxidation basal (mg?min
21?m
22)3 3 633 8 614 0 64
Lipid oxidation clamp (mg?min
21?m
22)7 62 {{ 24641 6 65
NOGD basal (mg?min
21?m
22)2 0 673 0 653 4 69
NOGD clamp (mg?min
21?m
22) 165622 {{ 58612 87614{{
PCOS pretreatment vs. controls, and the effect of pioglitazone treatment (30 mg/day for16 weeks) in PCOS patients. Students T-test for non-paired and paired data
used, respectively. Data represent means6SEM.
{{P,0.01 and
{P,0.05 vs. PCOS pretreatment. NOGD, non-oxidative glucose disposal.
doi:10.1371/journal.pone.0002466.t001
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ylation, translation factors, Human MitoDB 6, proteasome degradation, and
leucine_DN (genes downregulated in response to leucine starvation)
were significantly upregulated (FWER,0.05) (Table 3). A further
description of gene sets from GSEA can be obtained from the
GSEA homepage [22]. No pathways or gene sets were significantly
downregulated (FWER,0.05) when using MAPPFinder or GSEA
(Table S1 and S2).
Using GO, ribonucleoprotein complex and ribosome were the most
upregulated cellular components (C), and structural constituent of
ribosome was the most upregulated molecular function (F) term. The
most upregulated biological process (P) term was protein biosynthesis.
Oxidoreductase activity, acting on NADH or NADPH and NADH
dehydrogenase activity was among the top twenty upregulated GO
terms (Table S3). Signal transducer activity was the most downreg-
ulated molecular function (F) term, and cell communication was the
most downregulated biological process (P) term. Membrane and
related terms were the most downregulated cellular components
(C) (Table S4).
Evaluating the results from both GenMAPP and GSEA,
pathways representing OXPHOS genes, ribosomal proteins, mRNA
processing reactome, translation factors, and proteasome degradation were
significantly upregulated (FWER,0.05).
Pretreatment abnormalities in PCOS examined by global
pathway analysis
To test whether the transcriptional changes induced by
pioglitazone were correcting preexisting abnormalities in patients
Table 2. The top-ten most upregulated pathways analyzed with MAPPFinder 2.1.
MAPP Name Changed (n) Measured (n) ON MAPP (n) Changed (%) Z Score Permute p-value FWER p-value
Ribosomal proteins 69 88 88 78.4 10.9 ,0.0005 ,0.0005
Electron transport chain 61 91 105 67.0 8.6 ,0.0005 ,0.0005
mRNA processing reactome 62 125 127 49.6 5.7 ,0.0005 ,0.0005
Ubiquinone biosynthesis 32 54 81 59.3 5.3 ,0.0005 ,0.0005
Proteasome degradation 31 60 61 51.7 4.3 ,0.0005 0.003
Translation factors 26 50 50 52.0 4.0 ,0.0005 0.02
TGF beta receptor netpath 7 57 151 151 37.7 3.0 0.003 0.43
Striated muscle contraction 18 38 38 47.4 2.8 0.007 0.56
Androgen receptor netpath 2 43 112 112 38.4 2.7 0.008 0.65
TNF alpha NFkB netpath 9 66 186 187 35.5 2.6 0.005 0.75
A p-value,0.05 and a fold change $1.05 were used as the criteria for gene expression changes in PCOS patients after pioglitazone treatment. The z-score is based on
N=4998 genes linked to a MAPP and R=1355 of these genes meeting the criteria for change in expression. Changed (n): number of genes changed. Measured (n):
number of genes measured on the chip. On MAPP (n): number of genes on the MAPP. Changed (%): Changed (n) divided by Measured (n). FWER p-value: Family Wise
Error Rate.
doi:10.1371/journal.pone.0002466.t002
Table 3. Ranking of the 15 most upregulated gene sets analyzed with GSEA 2.0.1.
Name Size ES NES NOM p-value FDR q-value FWER p-value
Electron transport chain 97 20.60 23.00 ,0.0001 ,0.0001 ,0.0001
VOXPHOS 77 20.62 23.00 ,0.0001 ,0.0001 ,0.0001
Insulin 2F up 188 20.52 22.89 ,0.0001 ,0.0001 ,0.0001
Ribosomal proteins 88 20.53 22.61 ,0.0001 ,0.0001 ,0.0001
mRNA splicing 48 20.56 22.43 ,0.0001 ,0.0001 ,0.0001
mRNA processing 42 20.57 22.36 ,0.0001 ,0.0001 ,0.0001
Circadian exercise 42 20.56 22.32 ,0.0001 0.0002 0.0005
Rapamycin DN 189 20.40 22.19 ,0.0001 0.0007 0.002
Glutamine DN 251 20.38 22.12 ,0.0001 0.001 0.004
mRNA processing reactome 108 20.40 22.01 ,0.0001 0.003 0.01
Oxidative phosphorylation 58 20.44 21.97 ,0.0001 0.004 0.01
Translation factors 47 20.46 21.96 ,0.0001 0.004 0.02
Human MitoDB 6 2002 385 20.32 21.95 ,0.0001 0.005 0.02
Proteasome degradation 31 20.50 21.93 ,0.0001 0.005 0.02
Leucin DN 141 20.36 21.92 ,0.0001 0.005 0.03
Gene sets with a FWER,0.05 are shown. All genes on the chip were ranked by difference in expression after pioglitazone treatment of PCOS patients using the t-test. An
enrichment score (ES) was assigned to each gene, and the maximum ES (MES) was calculated for each gene set. NES: Enrichment score normalized for differences in
gene set size. FDR q-value: False Discovery Rate. FWER p-value: Family Wise Error Rate.
doi:10.1371/journal.pone.0002466.t003
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for analysis of gene expression changes between 10 PCOS patients
before treatment and 13 control subjects. Pretreatment muscle
biopsies from seven of the 10 PCOS patients analyzed in the
present study were also included in a previous microarray study, in
which the 16 most insulin resistant of all larger cohort of PCOS
patients [7] were compared with the same 13 control subjects [16].
In MAPPFinder, ribosomal proteins and the electron transport chain were
significantly downregulated (FWER,0.05) (Table 4). Using
GSEA, the expression of VOXPHOS, electron transport chain, valine,
leucine, and isoleucine degradation, propanoate metabolism, oxidative
phosphorylation, Human mitoDB 6, insulin 2F up, ribosomal proteins,
and fatty acid metabolism was significantly decreased (FWER,0.05)
(Table 5). No pathways and gene sets remained significantly
upregulated in MAPPFinder and GSEA after correction for
multiple testing (FWER) (Table S5 and S6). Applying GO, cell
communication was the most upregulated biological process (P),
enzyme regulator activity the most upregulated molecular function (F),
and intrinsic to membrane the most upregulated cellular component
(Table S7). The most downregulated GO terms were ribosome and
ribonucleoprotein complex (C), structural constituent of ribosome (F), and
protein biosynthesis (P) (Table S8).
Significant downregulation (FWER,0.05) of genes in pathways
representing OXPHOS and ribosomal proteins in PCOS patients
was identified using both GenMAPP and GSEA, and, in part,
validated our previous findings, where we used the same cohort of
control subjects and 16 insulin resistant PCOS patients [16].
Validation of pathway analysis with q-RT-PCR
The effect of pioglitazone treatment on expression of genes
involved in OXPHOS and ribosomal protein synthesis and
degradation was validated by q-RT-PCR (Table S9). All five
respiratory genes examined and UCP2 showed an increase in
expression (1.2–2.1 fold). Of these, NDUFA3 and SDHD were
significantly upregulated, and ATP5H tended (P=0.057) to be
upregulated (Figure 1A). The expression of genes known to
Table 4. The ten most downregulated pathways analyzed with MAPPFinder 2.1.
MAPP Name
Changed
(n)
Measured
(n)
ON MAPP
(n)
Changed
(%)
Z
Score
Permute
p-value
FWER
p-value
Ribosomal proteins 43 88 88 48.9 9.2 ,0.0005 ,0.0005
Electron transport chain 39 91 105 42.9 7.7 ,0.0005 ,0.0005
Aminoacyl tRNA biosynthesis 10 23 24 43.5 3.9 ,0.0005 0.07
Ubiquinone biosynthesis 17 54 81 31.5 3.5 0.002 0.18
Phenylalanine, tyrosine, and tryptophan biosynthesis 5 11 36 45.5 2.9 0.01 0.55
Inositol metabolism 1 1 9 100.0 2.4 0.13 0.96
Translation factors 13 50 50 26.0 2.3 0.02 0.97
mRNA processing reactome 27 125 127 21.6 2.2 0.03 0.98
Cell cycle G1 to S control reactome 16 67 67 23.9 2.2 0.04 0.99
Mitochondrial fatty acid betaoxidation 5 16 16 31.3 1.9 0.08 1
Insulin signaling 31 159 159 19.5 1.8 0.07 1
A p-value,0.05 and a fold change #21.05 were used as the criteria for gene expression changes between PCOS patients and control subjects. The z-score is based on
N=4998 genes linked to a MAPP and R=730 of these genes meeting the criteria for change in expression. Changed (n): number of genes changed. Measured (n):
number of genes measured on the chip. On MAPP (n): number of genes on the MAPP. Changed (%): Changed (n) divided by Measured (n). FWER p-value: Family Wise
Error Rate.
doi:10.1371/journal.pone.0002466.t004
Table 5. Ranking of the ten most downregulated gene sets analyzed with GSEA 2.0.1.
Name Size ES NES NOM p-value FDR q-value FWER p-value
VOXPHOS 77 0.61 3.06 ,0.0001 ,0.0001 ,0.0001
Electron transport chain 97 0.58 2.99 ,0.0001 ,0.0001 ,0.0001
Valine, leucine, and isoleucine degradation 36 0.55 2.30 ,0.0001 ,0.0001 ,0.0001
Propanoate metabolism 31 0.57 2.29 ,0.0001 ,0.0001 ,0.0001
Oxidative phosphorylation 58 0.46 2.13 ,0.0001 0.0007 0.002
Human mitoDB 6 2002 385 0.34 2.13 ,0.0001 0.0005 0.002
Insulin 2F up 188 0.35 2.05 ,0.0001 0.002 0.005
Ribosomal proteins 88 0.42 2.04 ,0.0001 0.002 0.007
Fatty acid metabolism 79 0.40 1.94 ,0.0001 0.006 0.03
Cell cycle arrest 32 0.45 1.83 0.005 0.01 0.06
All genes on the chip were ranked by difference in expression between PCOS patients and control subjects using the t-test. An enrichment score (ES) was assigned to
each gene, and the maximum ES (MES) was calculated for each gene set. NES: Enrichment score normalized for differences in gene set size. FDR q-value: False Discovery
Rate. FWER p-value: Family Wise Error Rate.
doi:10.1371/journal.pone.0002466.t005
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PPARGC1A (PGC-1a), PPARGC1B (PGC-1b) and NRF1,
increased 1.4–1.7 fold in response to pioglitazone. However, only
the increase in PGC-1a achieved statistical significance (P,0.02).
The mRNA level of PSMD6 was significantly increased, whereas
the increase (1.2–1.8 fold) in expression of the other genes
representing protein metabolism, RPS3A, RPL26, RPL41, and
UBE2B, was not significant (Figure 1B). Moreover, the gene
expression of enzymes involved in signaling to protein synthesis
including EIF2B4, FRAP1, S6K1 and 4EBP1 was unaltered in
response to pioglitazone. We did not evaluate gene expression
changes in skeletal muscle between patients with PCOS and
control subjects with q-RT-PCR, because these changes have been
validated recently [16].
Discussion
In this study, we examined the molecular signature of
pioglitazone therapy in skeletal muscle of women with PCOS
using global transcriptional profiling. We demonstrate that
increased insulin sensitivity induced by pioglitazone treatment is
associated with enhanced expression of genes representing
ribosomal protein biosynthesis and OXPHOS pathways, the
latter possibly mediated by an increased expression of PGC-1a.
Furthermore, we provide evidence that treatment with pioglita-
zone corrects preexisting downregulation of the same pathways in
skeletal muscle of patients with PCOS. These findings suggest that
the insulin-sensitizing effect of pioglitazone therapy may include
reversal of abnormalities in ribosomal protein biosynthesis and
mitochondrial oxidative phosphorylation.
In a recent microarray study [16], we found reduced expression
of OXPHOS genes in skeletal muscle biopsies obtained from the
most insulin resistant women among a larger cohort of PCOS
patients. Here, we confirm the downregulation of OXPHOS genes
in skeletal muscle of PCOS patients, who were randomly assigned
to treatment with pioglitazone in the same study cohort. In
addition, we found reduced expression of the ribosomal protein
pathway using both GenMAPP and GSEA. Although this
abnormality was not detected in our previous study of PCOS
patients [16], reduced gene expression of ribosomal proteins has
been reported in skeletal muscle [19] and adipose tissue [23] of
patients with type 2 diabetes in microarray-based studies.
Moreover, GO analysis showed that protein biosynthesis was the
most downregulated biological process term. These findings
support the hypothesis of an association between reduced protein
synthesis and insulin resistance in skeletal muscle, such as shown in
age-related sarcopenia [24,25]. However, Halvatsiotis et al [26]
reported no changes in muscle protein synthesis rate in patients
with type 2 diabetes, indicating that transcriptional downregula-
tion of the translational machinery is not necessarily reflected by a
decreased protein synthesis rate. Thus, whether muscle protein
synthesis rate is affected in PCOS patients remains to be
determined, but our data indicate that reduced gene expression
of ribosomal proteins and other pathways involved in protein
metabolism can not be attributed to hyperglycemia or obesity,
and, therefore, may represent an early defect associated with
insulin resistance in PCOS.
In the present study, the major finding is that the expression of
genes representing OXPHOS pathways is upregulated in skeletal
muscle of PCOS patients together with an increase in insulin
sensitivity in response to 16 weeks treatment with pioglitazone. To
our knowledge, no study has addressed the effects of TZDs on
muscle transcripts in PCOS. Similar to other studies using
pathway analysis [16,18,19], we observed small, but significant,
changes in expression of many genes representing OXPHOS
pathways, and some of these changes were also confirmed by q-
RT-PCR. Thus, these data provide evidence for an association
between small, but coordinated, improvements in expression of
OXPHOS genes in skeletal muscle and insulin sensitivity after
TZD treatment in women with PCOS. In a recent report, Pagel-
Langenickel et al [27] showed that improved glycemic control in
patients with type 2 diabetes treated with rosiglitazone for 12
weeks was independent of muscle mitochondrial content/activity.
Thus, rosiglitazone-mediated improvement in OXPHOS protein
content and citrate synthase activity was observed only in
individuals with relatively preserved maximal oxygen consumption
and mitochondrial copy numbers. Indeed, the difference between
our study and the study by Pagel-Langenickel et al [27] may reflect
a modestly longer duration of therapy (16 vs. 12 weeks), and the
broader PPAR isoform activation activity of pioglitazone versus
other TZDs such as rosiglitazone. Another possibility is that
intervention with TZDs earlier in the spectrum of insulin
resistance, e.g. in normoglycemic patients with PCOS, has a
greater effect on improving mitochondrial biogenesis than in
patients with type 2 diabetes. Moreover, expression of muscle
mRNA may not accurately reflect the abundance or activity of
OXPHOS proteins, and further studies are warranted to establish
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Figure 1. Effect of pioglitazone on expression of muscle genes. The mRNA expression level of selected genes was determined by quantitative
real-time PCR in nine patients with the polycystic ovary syndrome (PCOS). The relative expression of genes involved in oxidative phosphorylation (A)
and ribosomal protein biosynthesis including signaling to protein synthesis (B) are given. Regulated genes have mRNA levels different from 1.0
(dotted line). Data are means6SEM. *P,0.05.
doi:10.1371/journal.pone.0002466.g001
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TZDs is associated with increased content and function of muscle
mitochondria in PCOS.
PPARc ligands such as TZDs may enhance skeletal muscle
insulin sensitivity by inducing expression of genes like adiponectin
or genes involved in fatty acid uptake and oxidation in adipose
tissue which, in turn, convey signals to skeletal muscle [4,28].
Thus, recombinant adiponectin stimulates fatty acid oxidation and
glucose transport by activation of AMPK in rodent muscle
[29,30]. Other studies have shown that TZDs also may exert their
action independently of PPARc [31] and adiponectin, e.g. by
direct activation of AMPK [32,33]. Chronic activation of AMPK
is associated with increased mitochondrial biogenesis [34),
probably mediated by increased expression of PGC-1a and
NRF-1 [34,35]. In a single study of skeletal muscle from type 2
diabetic patients, Bandyopadhyay et al [12] showed that chronic
rosiglitazone therapy restored total AMPK activity. Contradictory
to this, the activity and protein content of AMPK in muscle were
not increased in our pioglitazone treated PCOS subjects, despite a
2-fold increase in circulating adiponectin [36]. This may indicate
that other mechanisms independently of AMPK mediated the
effect of TZDs on PGC-1a transcription, mitochondrial biogenesis
and insulin sensitivity in PCOS, e.g. through calcium/calmodulin-
dependent protein kinase and p38 mitogen-activated protein
kinase [37,38]. Recently, it was shown that the effects of AMPK
on gene expression of glucose transporter 4, mitochondrial genes
and PGC-1a, are mediated almost entirely by phosphorylation of
PGC-1a at specific sites [39]. Thus, another possibility is that
pioglitazone treatment of women with PCOS causes a transient
increase in AMPK activity, which then disappears in response to
enhanced OXPHOS gene expression and ATP synthesis.
Downregulation of PGC-1a is associated with reduced expression
of OXPHOS genes in skeletal muscle of women with PCOS [16],
patients with type 2 diabetes [18,19], and their first-degree relatives
[19]. In the current study, treatment with pioglitazone increased the
expression of PGC-1a in muscle of PCOS patients providing an
explanation at the molecular level for the observed upregulation of
OXPHOS genes. These data are consistent with a recent study
showing improved skeletal muscle oxidative enzyme activity and
restoration of PGC-1a gene expression upon rosiglitazone treatment
in obese patients with type 2 diabetes [40]. Whether the effect on
PGC-1a is mediated by the 2-fold increase in adiponectin, a direct
effect of pioglitazone on PPARc, or other as yet unknown effects of
pioglitazone remains to be clarified.
Another mechanism by which pioglitazone may enhance
OXPHOS gene expression in PCOS is via the effect of insulin
on mitochondrial biogenesis. Thus, studies have shown that acute
and chronic insulin infusion enhances the transcriptional activity
of genes involved in pathways such as energy metabolism in
skeletal muscle of healthy subjects and patients with type 2
diabetes [41–43]. In the present study, a pathway termed Insulin
2F Up, representing genes upregulated 2-fold by insulin
stimulation of skeletal muscle in healthy subjects [41], was
significantly upregulated in response to pioglitazone. Thus, it is
possible that the effect of pioglitazone on OXPHOS gene
expression is, at least in part, mediated by an improved insulin
action in muscle of PCOS patients. However, further studies are
needed to address the exact molecular mechanisms by which
pioglitazone treatment improves insulin action on transcriptional
activity in women with PCOS.
Using two different approaches for global pathway analysis, we
observed a consistent coordinated up-regulation of genes involved
in ribosomal protein biosynthesis in muscle of PCOS patients after
pioglitazone administration. A similar effect of TZDs on muscle
protein metabolism has, to our knowledge, not been reported
previously in PCOS or other insulin resistant conditions. Our data
indicate that the beneficial effects of pioglitazone therapy in PCOS
may include improved protein metabolism mediated either via an
enhanced anabolic action of insulin or directly via PPARc by an as
yet unknown mechanism. Several lines of evidence support a role
for increased insulin action. Thus, insulin promotes protein
synthesis by rapidly activating several components of the
translational machinery [44]. This response is elicited primarily
through phosphoinositide 3-kinase (PI3K) and Akt, which via
inhibition of GSK-3 causes dephosphorylation and activation of
eIF2B, and via activation of the mammalian target of rapamycin
(mTOR) signaling and phosphorylation of its downstream targets
ribosomal S6 kinase 1 (S6K1) and activation of eukaryotic
initiation factor 4E binding protein 1 (4EBP1), promotes initiation
and elongation [44]. Although our data provide evidence that the
increased transcription of ribosomal proteins was not caused by
changes in the expression of these key components in insulin
signaling to protein synthesis, we have recently reported that
impaired insulin action on Akt phosphorylation in muscle of
PCOS patients was normalized after treatment with pioglitazone
[36]. Thus, changes in the activity of mTOR signaling enzymes
and eIF2B provides a possible explanation for the observed
changes in the translational machinery before and after pioglita-
zone treatment. Moreover, recent microarray-based studies of
gene expression in skeletal muscle of healthy humans have shown
that the majority of the genes upregulated in response to acute
insulin infusion codes for proteins involved in transcriptional and
translational regulation including a number of ribosomal proteins
[41,45]. These reports lend support to the hypothesis that in the
long term, insulin also increases the cellular content of ribosomes
augmenting the capacity for protein synthesis. Interestingly, there
is experimental evidence that mTOR activity may also play a
regulatory role for mitochondrial metabolism [46]. Thus,
improved expression of genes involved in ribosomal protein
biosynthesis and mitochondrial biogenesis in skeletal muscle of
PCOS patients after long term pioglitazone therapy may involve
enhanced mTOR signaling mediated in part by an improved
anabolic action of insulin.
In summary, pioglitazone significantly upregulated a large
number of pathways in skeletal muscle of women with PCOS. The
most important finding was that pioglitazone increased the
expression of genes representing OXPHOS and ribosomal protein
biosynthesis, and that this effect corrected preexisting downregu-
lation of genes in the same pathways. Upregulation of OXPHOS
genes seems to involve increased expression of PGC-1a, and may
occur via an increase in adiponectin, a direct effect of TZD on
muscle PPAR gamma, and/or via an improved insulin action on
mitochondrial biogenesis. Further studies are required to assess the
precise mechanisms by which prolonged treatment with TZD
increases expression of OXPHOS and ribosomal protein biosyn-
thesis in skeletal muscle, and how these transcriptional changes
improves insulin sensitivity.
Materials and Methods
Subjects
Ten obese Caucasian women of reproductive age with PCOS
participated in the study to test the effect of pioglitazone therapy
on skeletal muscle gene expression. These subjects represent all
women with PCOS from whom a muscle biopsy was obtained
both before and after treatment with pioglitazone among a larger
cohort of PCOS patients [7,16]. Briefly, thirty PCOS patients
were randomly assigned to either pioglitazone or placebo. No
Muscle Gene Expression in PCOS
PLoS ONE | www.plosone.org 6 June 2008 | Volume 3 | Issue 6 | e2466effect with respect to hormonal or metabolic parameters was found
in the placebo group after treatment cessation.
Criteria for PCOS included irregular periods with cycle length
.35 days during the last year, free testosterone level above
reference interval (.0.035 nmol/l), and/or hirsutism (total Ferri-
man-Gallwey score.7) [7]. All PCOS patients accepted to
withdraw oral contraceptives .3 months before evaluation and
consented to use barrier contraception combined with spermato-
cidal cream during the study period. Control subjects had regular
menses, normal glucose tolerance, and no family history of
diabetes. Women with diabetes (fasting plasma glucose$7.0 m-
mol/l), hypertension, elevated liver enzyme levels, adrenal enzyme
defects, hyperprolactinemia, and hypothyroidism were excluded
from the study. Participants were excluded if they were pregnant.
All participants had normal results on screening blood tests of
hepatic and renal function. No subjects were taking any
medication known to affect hormonal or metabolic parameters.
Informed written consent was obtained from all subjects before
participation. The study was approved by the Local Ethics
Committee and was performed in accordance with the Helsinki
Declaration.
Study design
The design of the study has previously been described [7]. All
subjects were instructed to refrain from strenuous physical activity
for a period of 48-h before the euglycemic-hyperinsulinemic clamp
studies. The study subjects were admitted to the Diabetes
Research Centre at Odense University Hospital at 08:00 after
an overnight fast. To test the effect of a PPAR-c agonist,
pioglitazone (30 mg/day; Actos, Takeda, Lilly A/S, Lyngby,
Denmark) or placebo was administered to PCOS patients for a
period of 16 weeks. One patient receiving pioglitazone was
excluded from the study because of side effects (dizziness, ankle
edema, and anxiety). After the treatment period, the initial
evaluation program was repeated [7].
Rates of total glucose disposal rates (Rd), glucose and lipid
oxidation, and non-oxidative glucose disposal (NOGD) were
assessed by euglycemic-hyperinsulinemic clamp studies (4-h insulin
infusion, 40 mU7min per m
2) combined with indirect calorimetry
as described in detail previously [7]. Skeletal muscle biopsies were
obtained in the basal steady-state period of the clamp from the
vastus lateralis muscle using a modified Bergstro ¨m needle with
suction under local anaesthesia (10–15 ml of lidocain 2% (20 g/l)).
Muscle biopsies were immediately blotted free of blood, fat, and
connective tissue and frozen in liquid nitrogen within 30 s. Assays
for serum levels of insulin, free testosterone, luteinizing hormone
(LH), follicle-stimulating hormone (FSH), plasma glucose, triglyc-
eride, and free fatty acids (FFA) were as described in [7].
RNA extraction and microarray preparation
Total RNA was extracted from skeletal muscle tissue using the
TRIzol protocol (Life Technologies, Gaithersburg, MD). An extra
phenol-chloroform step was included as described previously [16].
Quantity of RNA was determined with a spectrophotometer, and
RNA of high quality was assessed using Agilent 2100 Bioanalyser
(Agilent Technologies, Palo Alto, CA) and degradometer software
[47]. The MessageAmpTM II-Biotin single round aRNA
amplification kit (Ambion, Austin, TX) was applied to convert
one mg of purified total RNA to biotin-labeled aRNA. Labeled
aRNA was fragmented as described in the Affymetrix manual
(Affymetrix, Santa Clara, CA) and hybridized to Affymetrix HG-
U133 Plus 2.0 chips. The 39/59 ratio of Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was below 1.42 for all chips
and confirmed high quality RNA.
Data processing
The R statistical software [48] was applied for data preprocess-
ing (www.bioconductor.org) and statistical analysis. Global
background correction of probe intensities was done by employing
a method implemented in the robust multi-array average (RMA)
method [49], and data was normalized by using constant
normalization. We tried to use variance stabilizing transformation
(VSN) for normalization as well. The results were comparable to
those obtained using constant normalization (data not shown).
Gene expression index calculation was done using model based
index calculation (MBEI) by Li & Wong [50]. Only perfect match
probes were included in data analysis. Differences in gene
expression between PCOS patients before and after pioglitazone
therapy and between PCOS patients and controls were calculated
for each gene by using Welch two sample t-test for paired and
unpaired data, respectively. An uncorrected P,0.05 was consid-
ered significant. Data are available from GEO (http://www.ncbi.
nlm.nih.gov/geo, Accession No. GSE8157).
Global pathway analysis
GenMAPP 2.1 [51] (MAPPFinder 2.1 (20)), and GSEA 2.0.1
[52] were employed to assess significantly regulated pathways,
gene ontology (GO) terms, and gene sets in the two data sets. In
MAPPFinder, a total of 203 pathways and 6251 GO terms were
applied whereas 189 gene sets were used in GSEA. An enrichment
score (ES) was calculated for each gene set in GSEA and the
statistical significance of the ES was estimated by an empirical
permutation test using 2.000 gene permutations to obtain the
nominal p-value.
Quantitative realtime PCR (Q-RT-PCR)
Total RNA from 9 PCOS patients before and after treatment
with pioglitazone was treated with DNAse I (USB, Cleveland,
Ohio) and reverse transcribed to single-stranded cDNA using
TaqMan reverse transcription reagents and random hexamer
primers (Applied Biosystems). One patient was not included in the
analysis because of a lack of RNA. TaqMan gene expression
assays (Applied Biosystems) and TaqMan Universal Master Mix
(Applied Biosystems) were used to quantify gene expression
changes using Applied Biosystems Prism 7700 (Supplemental
Table S9). b-actin (Applied Biosystems) was used as a housekeep-
ing gene to normalize gene expression levels. To perform the most
appropriate validation of microarray data, bioinformatic ap-
proaches such as NetAffx (www.Affymetrix.com), refseq (www.
ncbi.nlm.nih.gov), and Ensembl (www.ensembl.org) were used to
identify the TaqMan probe sequence for each gene, which has the
highest similarity to the Affymetrix probe set (Supplemental
Table S9).
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